Upregulated long non-coding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA-7/HOXB13 in esophageal squamous cell carcinoma

ZHIBO TAN1-3*, PEITAO ZHOU1*, ZHENRU ZHU1, YING WANG4, ZEQIN GUO1, MENGYING SHEN5, YAZHI XIAO1, WEIXI SHEN3 and DEHUA WU1

1Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515; 2Department of Radiation Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036; 3Department of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100; 4Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116; 5Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China

Received July 10, 2020; Accepted February 18, 2021

DOI: 10.3892/ijmm.2021.4911

Abstract. Long non-coding RNA LincIN has been reported to be overexpressed and to be involved in the metastasis of breast cancer. However, the expression and role of LincIN in esophageal squamous cell carcinoma (ESCC) remain unsolved. In the present study, LincIN expression was examined in ESCC by RT-qPCR, and the roles of LincIN in ESCC were determined using cell growth, migration and invasion assays. In addition, the effects of LincIN on nuclear factor 90 (NF90) and microRNA/miR (miR)-7 were examined by RNA immunoprecipitation assay, RT-qPCR, dual-luciferase reporter assay and western blot analysis. The results revealed that LincIN expression was significantly increased in ESCC tissues and cell lines. The increased expression of LincIN was positively associated with invasion depth, lymph node metastasis, TNM stage and a poor prognosis. Functional assays revealed that the overexpression of LincIN promoted ESCC cell growth, migration and invasion. Mechanistic analysis revealed that LincIN physically bound to NF90, enhanced the binding between NF90 and primary miR-7 (pri-miR-7), and further enhanced the inhibitory effects of NF90 on miR-7 biogenesis. Therefore, LincIN downregulated miR-7 expression in ESCC. The expression of miR-7 inversely correlated with that of LincIN in ESCC tissues. By downregulating miR-7, LincIN increased the expression of HOXB13, a target of miR-7. The overexpression of miR-7 or the depletion of HOXB13 both attenuated the tumor-promoting roles of LincIN in ESCC cell growth, migration and invasion. On the whole, the findings of the present study suggest that LincIN is overexpressed and plays an oncogenic role in ESCC via the regulation of the NF90/miR-7/HOXB13 axis. Thus, LincIN may prove to be a promising prognostic biomarker and therapeutic target for ESCC.

Introduction

Esophageal carcinoma is one of the most aggressive gastrointestinal malignancies and accounts for the sixth leading cause of cancer-related mortality worldwide; there were 572,000 estimated new cases and 509,000 estimated deaths in 2018 worldwide (1). Esophageal squamous cell carcinoma (ESCC) is the major histological type, which accounts for approximately 90% of all esophageal carcinoma cases (2). Due to the difficulty in the early diagnosis of ESCC, the majority of patients with ESCC are not suitable for radical surgical resection (3). The prognoses of patients with ESCC are extremely poor (4). Further revealing the critical molecular mechanisms underlying the initiation and development of ESCC would promote the findings of novel therapeutic targets and prognostic biomarkers for ESCC.

Genome and transcriptome sequencings have found that the majority of the human genome is transcribed; however, only approximately 2% of the human genome encodes for proteins (5). Non-coding RNAs comprise >90% of the human transcriptome (6). Long non-coding RNAs (lncRNAs) and...
miRNAs (miRNAs or miRs) are two classes of important regulatory non-coding RNAs, which have been revealed to play critical roles in various pathophysiological statuses (6,7). IncRNAs are a class of RNAs with >200 nucleotides in length and limited protein-coding potential (8). Accumulating evidence has indicated that a number of IncRNAs are dysregulated and play important roles in various diseases, including cancers (9-17). IncRNAs have been revealed to regulate various biological functions of cancer cells, such as growth, cycle, apoptosis, migration, invasion, senescence, drug resistance and others (18-25). The mechanisms of action of IncRNAs are diverse. IncRNAs can directly bind proteins, mRNAs, miRNAs, or DNAs, and further modulate the location, expression and function of the interacted partners (26-29).

miRNAs are another class of regulatory non-coding RNAs with 19-25 nucleotides in length (30). Consistent with IncRNAs, a number of miRNAs have been revealed to be dysregulated and to play important roles in various diseases (31-35). miRNAs negatively regulate the expression of their targets by binding to the 3'-untranslated regions (3'UTRs) of target mRNAs, and further causing translational inhibition and/or target mRNAs degradation (36-39).

IncRNA LincIN (long intergenic non-coding RNA between ITGB1 and NRPI) was recently identified to be overexpressed in human breast tumors and to be associated with a poor prognosis of patients with breast cancer (40). Furthermore, LincIN was revealed to promote breast tumor cell migration and invasion by binding nuclear factor 90 (NF90) (40). However, the expression, clinical significance, biological role and mechanisms of action of LincIN in ESCC remain unknown.

In the present study, LincIN expression was measured in ESCC by RT-qPCR, and the roles of LincIN in ESCC were detected using cell growth, migration and invasion assays. In addition, and the mechanisms of action of LincIN were investigated by RNA immunoprecipitation assay, RT-qPCR, dual-luciferase reporter assay and western blot analysis.

Materials and methods

Clinical specimens. A total of 56 pairs of ESCC tissues and adjacent noncancerous tissue specimens were acquired from patients with ESCC who received surgical resection at Nanfang Hospital, Southern Medical University (Guangzhou, China) between February, 2016 and December, 2017. The clinical specimens were immediately frozen in liquid nitrogen and stored at -80°C after surgery. All clinical specimens were diagnosed by histopathological detection. Written informed consent was acquired from all participants. The use of clinical specimens was reviewed and approved by the Nanfang Hospital Institutional Review Board (Guangzhou, China).

Cells and cell culture. The human immortalized normal esophageal epithelial cell line, Het-1A, was acquired from the American Type Culture Collection (ATCC, cat. no. CRL-2692). The ESCC cell lines, TE-1 (cat. no. TCHu 89), KYSE150 (cat. no. TCHu 236) and Eca-109 (cat. no. TCHu 69), were acquired from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Het-1A cell lines were maintained in BEBM (Lonza Group, Ltd.). ESCC cell lines were maintained in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.). All cells were cultured in medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at a humidified incubator with 5% CO₂ at 37°C.

Plasmid construction. LincIN full-length sequences were PCR-amplified using the Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher Scientific, Inc.) and the primers, 5'-CCC AGC TTT CAC TTG TAG TCA CCC AGG CT-3' (sense) and 5'-GCT TAG ATG CTG TGA AAT AGT TAATGCTG-3' (antisense). Subsequently, the PCR products were sub-cloned into the HindIII and XbaI sites of the pcDNA3.1 (+) plasmid (Invitrogen; Thermo Fisher Scientific, Inc.). In total, 2 independent oligonucleotides inhibiting LincIN expression were synthesized and inserted into the Supersilencing shRNA (short hairpin RNA) expression plasmid pGPU6/Neo (GenePharma, Inc.), named LincIN-shRNA1 and LincIN-shRNA2. The targeted sequences of the LincIN shRNAs were as follows: 5'-GACATTATGCAGAGATG GCCA-3' (LincIN-shRNA1) and 5'-CAGTTGTGTCACTCTA CTCAGT-3' (LincIN-shRNA2) (40). The HOXB13 3'UTR containing miR-7 target sites were PCR-amplified using the Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher Scientific, Inc.) and the primers, 5'-CGAGGTCTCCCCCTCCA TTACACCTTCCAC-3' (sense) and 5'-GCTCAGATCTC CTCCTCGTCTCCTTT-3' (antisense). The PCR products were then sub-cloned into the SacI and XbaI sites of pmirGLO plasmid (Promega Corporation).

Transfection of plasmids and miRNAs. miR-7 mimics and miRNAs negative control (NC) were purchased from GenePharma, Inc. HOXB13 specific shRNA (HOXB13-shRNA) and scrambled shRNA which was used as a negative control were purchased from GeneCopoeia, Inc. The transfections of plasmids (2.5 µg) and miRNAs (10 pmol) were carried out using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the protocol. At 48 h following transfection, subsequent experimentation was performed.

Construction of stable cell lines. The LincIN overexpression plasmid and control pcDNA3.1 plasmid were transfected into TE-1 cells. TE-1 cells were established from a well-differentiated human squamous cell carcinoma of the esophagus and had a male karyotype (41). TE-1 has a mutation at codon 272 of p53, leading to p53 activity impairment (42). At 48 h following transfection, the cells were selected with neomycin for 4 weeks to obtain LincIN stably overexpressed and control TE-1 cells. LincIN-specific shRNAs (2.5 µg) and control shRNA (2.5 µg) were transfected into the Eca-109 cells. The Eca-109 cells were derived from a human esophageal carcinoma in 1973 (43). Eca-109 harbors wild-type p53 (44). At 72 h following transfection, the cells were selected with neomycin for 4 weeks to obtain LincIN stably-depleted and control Eca-109 cells. 2x10⁶ transducing units of miR-7 overexpression lentivirus (GeneCopoeia, Inc.) was infected into LincIN stably overexpressing TE-1 cells. At 96 h following infection, the cells were selected with neomycin and puromycin for 4 weeks to obtain LincIN and miR-7 simultaneously stably overexpressed TE-1 cells. HOXB13-specific shRNAs (2.5 µg) were transfected into LincIN stably overexpressing TE-1 cells. At 72 h following transfection, the cells were selected with neomycin and...
puromycin for 4 weeks to obtain HOXB13 stably depleted and simultaneously LincIN stably overexpressing TE-1 cells.

Total RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. The RNA was then used to carry out reverse transcription using the M-MLV Reverse Transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.). The first-stand cDNA generated from reverse transcription was used to carry out quantitative polymerase chain reaction (qPCR) with SYBR Premix Ex Taq™ II (Takara Biotechnology Co., Ltd.) on an ABI7500 System (Applied Biosystems; Thermo Fisher Scientific, Inc.) following the standard SYBR-Green PCR protocols. The qPCR cycling conditions were as follows: 95˚C for 30 sec, then 40 cycles at the conditions of 95˚C for 5 sec, 60˚C for 20 sec, and 72˚C for 20 sec. The RT-qPCR primers were as follows: LincIN, 5'-AACAGGGGGATCGGAACA-3' (forward) and 5'-CCAAGGACACAGAGT-3' (reverse); HOXB13, 5'-TGA CTCCTCTTGCCTGTT-3' (forward) and 5'-GAACCTGTG AGCCGCAAATGCT-3' (reverse); β-actin, 5'-GGGAATTCG TGCGTGACATTAAG-3' (forward) and 5'-TGATGTTGTC GC GTACAGGCTTGG-3' (reverse). For the quantification of the expression of miR-7 and pri-miR-7, RT-qPCR was carried out using the TaqMan microRNA assays (Applied Biosystems; Thermo Fisher Scientific, Inc.) and TaqMan pri-miRNA assays (Applied Biosystems; Thermo Fisher Scientific, Inc.) respectively following the manufacturer's protocols. β-actin was used as a reference gene for the quantification of LincIN, HOXB13 and pri-miR-7. U6 was used as a reference gene for the quantification of miR-7. The quantification of RNA expression was calculated using the 2^−ΔΔCq method (45).

Western blot analysis. Total proteins were extracted from the TE-1 and Eca-109 cells using RIPA buffer (Beyotime Institute of Biotechnology) supplemented with protease inhibitors (Beyotime Institute of Biotechnology). Protein concentrations were determined by bichinchoninic acid (BCA) assay with the BCA Protein Assay kit (Beyotime Institute of Biotechnology) following the manufacturer's protocol. Equal amounts of proteins (10 µg) were separated by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred onto PVDF membranes (EMD Millipore). After blocking with 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20 (TBST) at room temperature for 2 h, the membranes were incubated with primary antibodies against HOXB13 (1:1,000, cat. no. 90944, Cell Signaling Technology, Inc.) or β-actin (1:10,000, cat T0022, Affinity Biosciences) overnight at 4˚C. After washing with TBST buffer, the membranes were incubated with IRDye 680RD goat anti-mouse IgG secondary antibody (1:10,000, cat. no. 925-68070, LI-COR Biosciences) or IRDye 800CW goat anti-rabbit IgG secondary antibody (1:10,000, cat. no. 926-32211, LI-COR Biosciences) at room temperature for 1 h, followed by detection on an Odyssey infrared scanner (LI-COR Biosciences). β-actin was used as a loading control.

Cell growth assays. Cell growth was assessed using a Cell Counting kit-8 (CCK-8) and 5-ethynyl-2-deoxyuridine (EdU) incorporation assays (27). For CCK-8 assay, the TE-1 and Eca-109 cells were seeded at 2×10^4 cells/well into 96-well plates. After being incubated for 24, 48, or 72 at 37˚C, 10 µl CCK-8 solution (Dojindo Laboratories, Inc.) were added to each well. The optical density values at 450 nm were measured with an enzyme-linked immune detector to indicate cell viability. EdU incorporation assay was performed using the Cell-Light™ EdU Apollo® 643 In Vitro Imaging kit (Guangzhou RiboBio Co., Ltd.) following the manufacturer's instructions. The results were detected using a Zeiss photomicroscope (Carl Zeiss AG) and counting was performed based on at least 10 random visual fields.

Transwell cell migration and invasion assays. Cell migration and invasion were assessed using Transwell assays (46). The TE-1 and Eca-109 cells suspended in serum-free medium were plated in the upper chamber of Transwell inserts (8 µm-pore size, EMD Millipore) with Matrigel (for invasion assay) or without Matrigel (for migration assay). Medium containing 20% fetal bovine serum was plated into the lower chamber. Following incubation for 48 h at 37˚C, cells remaining on the upper chamber were wiped away using a cotton swab. Cells migrating into the lower surfaces of the Transwell inserts were fixed in methanol and stained with 0.5% crystal violet (Beyotime Institute of Biotechnology) at room temperature for 30 min. The results were detected using a Zeiss photomicroscope and counted based on at least 10 random visual fields.

RNA immunoprecipitation (RIP) assay. RIP assays were carried out in the TE-1 and Eca-109 cells using the EZ-Magna RIP™ RNA Binding Protein Immunoprecipitation kit (EMD Millipore) and primary antibody against NF90 (5 µg, ab131004, Abcam). The enriched RNA (LincIN and pri-miR-7) was quantified by RT-qPCR as described above.

Dual-luciferase reporter assay. Luciferase reporter plasmid pmirGLO containing HOXB13 3’UTR (50 ng) was co-transfected with LincIN overexpression plasmid (50 ng) and miR-7 mimics (1 pmol) into TE-1 cells. Luciferase reporter plasmid pmirGLO containing HOXB13 3’UTR (50 ng) was co-transfected with LincIN specific shRNAs (50 ng) into Eca-109 cells. Following incubation for 48 h at 37˚C, the Firefly luciferase and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega Corporation).

Statistical analysis. GraphPad Prism software (version 5.0) was employed to carry out statistical analyses. For comparisons, the Wilcoxon signed-rank test, Pearson's Chi-squared test, Log-rank test, one-way ANOVA followed by Dunnett's multiple comparison test, the Student's t-test, and Pearson's correlation analysis were performed as indicated. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

LincIN expression is increased in ESCC and is associated with a poor prognosis of patients with ESCC. To confirm the expression pattern of LincIN in ESCC, the expression of
LincIN was examined in 56 pairs of ESCC tissues and adjacent non-cancerous tissues by RT-qPCR. The results revealed that the expression of LincIN was significantly increased in ESCC tissues compared with adjacent non-cancerous tissues (Fig. 1A). The analyses of the clinicopathological characteristics of these 56 ESCC cases revealed that the increased expression of LincIN was positively associated with an advanced tumor invasion depth, lymph node metastasis and TNM stage (Table I). Patients with ESCC with a higher expression of LincIN had a shorter survival time than those with a lower expression of LincIN (Fig. 1B). In addition, the expression of LincIN was significantly increased in the ESCC cell lines, TE-1, KYSE150 and Eca-109, compared with the normal esophageal epithelial cell line, Het-1A (Fig. 1C). Collectively,
these results suggested that LincIN expression was increased in ESCC tissues and cell lines, and was associated with an advanced clinical stage and a poor prognosis of patients with ESCC.

Overexpression of LincIN promotes ESCC cell growth, migration, and invasion. To explore the biological roles of LincIN in ESCC, LincIN was stably overexpressed in the TE-1 cells, which exhibited the lowest LincIN expression out of the 3 ESCC lines (Fig. 1C), by transfection with LincIN overexpression and control plasmids (Fig. 2A). CCK-8 assays revealed that the overexpression of LincIN promoted ESCC cell growth (Fig. 2B). EdU incorporation assays further verified the roles of LincIN overexpression in promoting ESCC cell growth (Fig. 2C). Transwell migration and invasion assays also revealed that the overexpression of LincIN promoted ESCC cell migration and invasion (Fig. 2D and E). Collectively, these results suggested that the overexpression of LincIN promoted ESCC cell growth, migration and invasion.

Knockdown of LincIN inhibited ESCC cell growth, migration, and invasion. To further explore the biological roles of LincIN knockdown in ESCC, LincIN expression was stably depleted in the Eca-109 cells, which exhibited the highest expression of LincIN out of the 3 ESCC cell lines, by transfection with 2 independent LincIN-specific shRNAs (Fig. 3A). CCK-8 and EdU incorporation assays revealed that the knockdown of LincIN inhibited ESCC cell growth (Fig. 3B and C). Transwell migration and invasion assays also revealed that the knockdown of LincIN inhibited ESCC cell migration and invasion (Fig. 3D and E). Collectively, these results suggested that the knockdown of LincIN inhibited ESCC cell growth, migration and invasion.

LincIN enhances the suppressive effects of NF90 on miR-7 biogenesis. LincIN was previously identified as a NF90-binding IncRNA in breast cancer (40). Therefore, the present study further investigated whether LincIN also bound NF90 in ESCC. RIP assays revealed that LincIN was specifically enriched in the NF90 antibody group, suggesting the binding between LincIN and NF90 (Fig. 4A). NF90 has been reported to suppress miR-7 biogenesis by binding primary miR-7 (pri-miR-7) (47). miR-7 is a well-known tumor suppressor in a number of types of cancer, including ESCC (46,48,49). Therefore, the present study further explored the effects of LincIN on NF90/miR-7. RIP assays revealed that the overexpression of LincIN promoted, while the knockdown of LincIN suppressed the binding between NF90 and pri-miR-7 (Fig. 4B and C), suggesting that LincIN enhanced the binding between NF90 and pri-miR-7. Subsequently, the
expression levels of pri-miR-7 and mature miR-7 in ESCC cells in which LincIN was stably overexpressed or depleted were measured by RT-qPCR. The results displayed that the overexpression of LincIN induced the accumulation of pri-miR-7 and the downregulation of mature miR-7 in ESCC cells (Fig. 4D and E). The knockdown of LincIN downregulated the accumulation of pri-miR-7 and upregulated mature miR-7 in ESCC cells (Fig. 4F and G). Collectively, these
results suggested that LincIN enhanced the suppressive roles of NF90 on miR-7 biogenesis and therefore, downregulated the mature miR-7 level.

miR-7 expression is decreased and inversely correlates with LincIN expression in ESCC tissues. To determine whether the downregulation of miR-7 by LincIN exists in vivo, the expression of miR-7 was measured in the same 56 pairs of ESCC tissues and adjacent non-cancerous tissues used in Fig. 1. Conversely to the expression pattern of LincIN, miR-7 expression was significantly decreased in ESCC tissues compared with that in adjacent non-cancerous tissues (Fig. 5A). Furthermore, a statistically significant inverse correlation between miR-7 and LincIN expression levels was found in these 56 ESCC tissues (r=−0.4024, P=0.0021, Fig. 5B).

LincIN upregulates HOXB13 expression by suppressing miR-7. HOXB13 was previously identified as a critical target of miR-7 and it was found to mediate the tumor suppressive roles of miR-7 (46,50). Therefore, the present study further examined the effects of LincIN on HOXB13. Dual-luciferase reporter assays revealed that the overexpression of LincIN significantly upregulated the 3'UTR activity of HOXB13, which was reversed by the concurrent overexpression of miR-7 (Fig. 6A and B). Reciprocally, the knockdown of LincIN significantly reduced the 3'UTR activity of HOXB13 (Fig. 6C). RT-qPCR assays revealed that the overexpression of LincIN significantly upregulated the HOXB13 mRNA level, which was reversed by the concurrent overexpression of miR-7 (Fig. 6D). Reciprocally, the knockdown of LincIN significantly reduced the HOXB13 protein level, which was reversed by the concurrent overexpression of miR-7 (Fig. 6F). Western blot assays revealed that the overexpression of LincIN markedly upregulated the HOXB13 protein level, which was reversed by the concurrent overexpression of miR-7 (Fig. 6G). Collectively, these results suggested that LincIN upregulated HOXB13 by suppressing miR-7.

Overexpression of miR-7 or depletion of HOXB13 attenuates the promoting effects of LincIN in ESCC cell growth, migration and invasion. To examine whether miR-7/HOXB13 mediate the roles of LincIN in promoting ESCC cell growth, migration and invasion, miR-7 was stably overexpressed or HOXB13 was depleted in TE-1 cells stably overexpressing LincIN (Fig. 7A). CCK-8 and EdU incorporation assays revealed that both miR-7 overexpression and HOXB13 depletion attenuated the promoting effects of LincIN on ESCC cell growth.
Figure 5. miR-7 expression is decreased and inversely correlates with LincIN expression in ESCC tissues. (A) Expression of miR-7 in 56 pairs of ESCC tissues and adjacent noncancerous tissues detected by RT-qPCR. P<0.0001, determined by Wilcoxon signed-rank test. (B) Correlation between miR-7 and LincIN expression level in 56 ESCC tissues was analysed; r=-0.4024, P=0.0021, determined by Pearson's correlation analysis. ESCC, esophageal squamous cell carcinoma.

Figure 6. LincIN upregulates HOXB13 expression by suppressing miR-7. (A) Expression of miR-7 in TE-1 cells transfected with miR-7 mimics or miRNAs negative control (NC) detected by RT-qPCR. (B) Luciferase activity in TE-1 cells co-transfected with LincIN overexpression plasmid, miR-7 mimics and luciferase reporter containing HOXB13 3'UTR. Results are shown as the relative ratio of Firefly luciferase activity to Renilla luciferase activity. (C) Luciferase activity in Eca-109 cells co-transfected with LincIN specific shRNAs and luciferase reporter containing HOXB13 3'UTR. Results are shown as the relative ratio of Firefly luciferase activity to Renilla luciferase activity. (D) Expression of HOXB13 mRNA in TE-1 cells co-transfected with LincIN overexpression plasmid and miR-7 mimics detected by RT-qPCR. (E) Expression of HOXB13 protein in TE-1 cells co-transfected with LincIN overexpression plasmid and miR-7 mimics detected by western blot analysis. (F) Expression of HOXB13 protein in LincIN stably depleted and control Eca-109 cells detected by western blot analysis. Results are shown as the means ± SD from 3 separate experiments. *P<0.01, **P<0.001, vs. control or control-shRNA group; ns, not significant, determined by one-way ANOVA followed by Dunnett's multiple comparisons test. ESCC, esophageal squamous cell carcinoma.
(Fig. 7B and C). Transwell migration and invasion assays also revealed that both miR-7 overexpression and HOXB13 depletion attenuated the promoting effects of LincIN on ESCC cell migration and invasion (Fig. 7D and E). Collectively, these results suggested that the overexpression of miR-7 or depletion of HOXB13 both attenuated the promoting effects of LincIN on ESCC cell growth, migration and invasion.

**Discussion**

As one of the most lethal types of cancer, ESCC involves complex molecular mechanisms which remain unclear. Whole-exome sequencings have identified a number of mutations in ESCC, including *TP53*, *CCND1*, *CDKN2A*, *NFE2L2*, *RB1*, *KMT2D*, *KMT2C*, *EP300*, *FAT1*, *NOTCH1* and others (51). Furthermore, transcriptome sequencing analyses have identified a number of differentially expressed mRNAs and lncRNAs in ESCC (52). The expression and roles of several lncRNAs in ESCC have also been investigated (50). **lncRNA ccAT1** has been shown to be upregulated in ESCC tissues and to be associated with a poor survival (50). ccAT1 promotes ESCC cell proliferation and migration by downregulating SPRY4 and upregulating HOXB13 (50). CCAT1 binds and recruits EZH2 and SUV39H1 to epigenetically silence
lncRNA LincIN, whose encoding gene is located on chromosome 10p11-12, was first identified in breast tumors (40). LincIN is overexpressed in human breast tumors, and is associated with a poor prognosis of patients with breast cancer, and is involved in the metastasis of breast cancer (40). However, the expression, clinical significance and role of LincIN in other diseases remain unknown. In the present study, it was found that LincIN expression was also significantly increased in ESCC tissues and cell lines, and was associated with an advanced clinical stage and a poor prognosis of patients with ESCC. Functional experiments revealed that the overexpression of LincIN promoted ESCC cell growth, migration and invasion. The knockdown of LincIN inhibited ESCC cell growth, migration and invasion. Thus, these data suggested LincIN as a promising prognostic biomarker and therapeutic target for ESCC.

The mechanisms of action of IncRNAs are complex. One of the main mechanisms is to bind proteins (13). In breast tumors, LincIN was revealed to bind NF90 (40). NF90, also known as ILF3, is an RNA binding protein (63). By binding double-stranded RNA, NF90 regulates gene expression and/or mRNA stabilities (64). In addition, by binding pri-miRNAs, NF90 modulates miRNAs biogenesis (47). The biogenesis of miR-7, which plays tumor suppressive roles in a number of types of cancer, has been reported to be suppressed by NF90 (46,47). Therefore, the present study further investigated the effects of LincIN on NF90/miR-7. It was verified that LincIN directly bound NF90 in ESCC cells. Moreover, LincIN promoted the binding between NF90 and pri-miR-7, thereby enhancing the suppressive roles of NF90 on miR-7 biogenesis. It was then verified that LincIN downregulated mature miR-7. Conversely to LincIN, miR-7 expression was significantly decreased in ESCC tissues. The expression of mature miR-7 was significantly and inversely associated with that of LincIN in ESCC tissues, supporting the negative regulation of miR-7 by LincIN. HOXB13 is a direct target of miR-7 and plays oncogenic roles in several types of cancer, including ESCC (46,50). By repressing miR-7, LincIN was verified to upregulate HOXB13 expression in ESCC cells. Functional rescue assays demonstrated that the overexpression of miR-7 or depletion of HOXB13 attenuated the promoting effects of LincIN on ESCC cell growth, migration and invasion, which further suggested that miR-7/HOXB13 are critical mediators of the oncogenic roles of LincIN in ESCC. Similar roles of IncRNAs in miRNAs biogenesis have also been reported in other types of cancer, such as the promotion of miR-145 biogenesis by lncRNA-ATB in bladder cancer and the disruption of miR-125b biogenesis by LINC01578 in breast cancer (63,65). The detailed mechanisms underlying the inverse effects of IncRNAs on the biogenesis of different miRNAs warrant further investigation.

Apart from miR-7, NF90 has also been reported to suppress p21 translation, upregulate hypoxia inducible factor-1α (HIF-1α) and VEGF-A, stabilize PARP1 mRNA, and facilitate DICER expression (40,64,66,67). Thus, whether LincIN modulates p21, HIF-1α, VEGF-A, PARP1 and DICER via interacting with NF90 in ESCC cells needs to be further investigated. Nevertheless, the present study identified a novel mechanism of IncRNA in ESCC and provides a novel target against ESCC.

In conclusion, the present study demonstrates that IncRNA LincIN is highly expressed in ESCC, and is associated with an advanced clinical stage and a poor prognosis of patients with ESCC. LincIN promotes ESCC cell growth, migration and invasion by binding NF90, suppressing the biogenesis of miR-7 and upregulating HOXB13. The data presented herein suggest that LincIN may be a promising prognostic biomarker and therapeutic target for ESCC.

Acknowledgements

The authors would like to thank Mr. Peng Jiang for providing assistance with language editing.

Funding

The present study was supported by the National Nature Science Foundation of China (grant nos. 81672756, 81872399, 81772631 and 81572849), the Natural Science Foundation of Guangdong Province (grant no. 2018A030313530), the Chinese Scholarship Council (grant no. 201908440010), the Shenzhen Healthcare Research Project (grant no. SZFZ2017105), the Seedling Program of Shenzhen Hospital, Southern Medical University (grant no. 2016MM06) and the Sanming Project of Medicine in Shenzhen (grant no. SZSM201612041).

Availability of data and materials

All data generated or analyzed during this study are included in this published article or are available from the corresponding author on reasonable request.

Authors' contributions

DW and ZT designed the study. ZT, WS, PZ, YW, ZZ, ZG and MS performed the experiments. DW, ZT and YX performed the statistical analysis. DW and ZT wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The use of clinical specimens was reviewed and approved by the Nanfang Hospital Institutional Review Board (Guangzhou, China). Written informed consent was acquired from all participants.

Patient consent for publication

Not applicable.
Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.

2. Pennathur A, Gibson MK, Jove BA and Luketich JD: Oesophageal carcinoma. Lancet 381: 400-412, 2013.

3. Wang AL and Elmqvist A: Esophageal cancer. N Engl J Med 373: 2499-2509, 2014.

4. Sjoquist KM, Burmeister BH, Smitts BM, Zalberg J, Simes RJ, Barbour A, Gimbiski V; Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 12: 681-692, 2011.

5. Cárnicini P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard F, Wells C, et al: The transcriptional landscape of the mammalian genome. Science 309: 1559-1563, 2005.

6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.

7. Rustgi AK and El-Serag HB: Esophageal carcinoma. N Engl J Med 371: 2499-2509, 2014.

8. Siddiqui S, Liu JY, DiCesare J, Wu Y, Tatara K, Yang H, et al: The transcriptional landscape of the mammalian genome. Nat Cell Biol 20: 492-502, 2018.

9. Chen HY, Yang F, Wang F, Ma Jz, Guo Y, Tao Qf, Liu F, Pan W, Wang T, Zhou Cc, et al: Long non-coding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25: 666-681, 2014.

10. Zhang C, Yuan J, Hu H, Chen W, Liu M, Zhang J, Sun S and Guo Z: Long non-coding RNA CHDCHD4P4 promotes epithelial-mesenchymal transition and inhibits cell proliferation in calcium oxalate-induced kidney damage. Braz J Med Res 51: e6536, 2017.

11. Yin D, Lu X, Su J, He X, De W, Yang J, Li W, Han L and Zhang E: Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non-small cell lung cancer cell proliferation by epigenetically repressing p21 expression. Mol Cancer 17: 92, 2018.

12. Schmitt AM and Chang HY: Long noncoding RNAs in cancer pathways. Cancer Cell 29: 452-463, 2016.

13. Hu WL, Jin L, Xu A, Wang YF, Thorne RF, Zhang XD and Wu M: GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. Nat Cell Biol 20: 492-502, 2018.

14. Li JK, Cheng C, Liu JY, Shi Jz, Liu SP, Liu B, Wu DS, Fang ZY, Bao Y, Jiang MM, et al: Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPP3 and activating p38-MAPK signaling. Mol Cancer 16: 99, 2017.

15. Wang Y, Zheng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y and Lu Z: Long noncoding RNA DANC4 promotes epithelial-mesenchymal transition and inhibits cell proliferation in calcium oxalate-induced kidney damage. J Med Phy Res 51: e6536, 2017.

16. Wang Y, Zheng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y and Lu Z: Long noncoding RNA DANC4, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in oesophageal carcinoma. Mol Cancer 17: 89, 2018.

17. Zhu H, Zheng T, Yu J, Zhou L and Wang L: LncRNA XIST accelerates cervical cancer progression via upregulating fus through competitively binding with miR-200a. Biomed Pharmacother 105: 789-797, 2018.

18. Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, et al: The LINK-A IncRNA interacts with PtdIns(3,4,5) P3 to hyperactivate AKT and confer resistance to AKT inhibition. Nat Cell Biol 19: 235-251, 2017.

19. Grelet S, Link LA, Howley B, Obelliane N, Panalisamy V, Gangaraju VK, Diehl JA and Howe PH: A regulated PNUTS mRNA to IncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol 19: 1105-1115, 2017.

20. Gilot D, Mignault G, Bachelot L, Journoi J, Rogiers A, Dominou-Fournet E, Mardaret N, Moutet R, Llano-Mel ML, Mari B, et al: A non-coding function of TYPRR1 mRNA promotes melanoma growth. Nat Cell Biol 19: 1348-1357, 2017.

21. Tsai KW, Lo YH, Liu H, Yeh CY, Chen YZ, Hsu CW, Chen WS and Wang JH: Linc00659, a long noncoding RNA, acts as novel oncogene in regulating cancer cell growth in colorectal cancer. Mol Cancer 17: 72, 2018.

22. Zhang S, Wang W, Liu G, Xie S, Li Q, Li Y and Lin Z: Long non-coding RNA HOTTIP promotes hyoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEBl axis. Biomed Pharmacother 95: 711-720, 2017.

23. Michelini F, Pitchiaya S, Vitelli V, Sharma S, Gioia U, Pessina F, Cabrini M, Wang Y, Cai H, Li Z, Lannelli F, et al: Long Non-coding IncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks. Nat Cell Biol 19: 1400-1411, 2017.

24. Yuan JH, Liu XN, Wang TT, Pan W, Tao QF, Zhou WP, Wang F and Sun SH: The MBP3 splicing factor promotes hepatocellular carcinoma by increasing PXX expression through the alternative splicing of IncRNA-PSXN-AS1. Nat Cell Biol 19: 820-832, 2017.

25. Su R, Cao S, Ma J, Liu Y, Liu X, Zheng J, Chen J, Liu L, Cai H, Li Z, et al: Knockdown of SOX2OT inhibits the malignant biological behaviors of glioblastoma stem cells via up-regulating the expression of miR-194-5p and miR-122. Mol Cancer 16: 171, 2017.

26. Xiao J, Zhang L, Zheng L, Hong Y and Zhao L: LncRNAATCF7 promotes the growth and self-renewal of glioma cells via suppressing the miR-200c-EpCAM axis. Biomed Pharmacother 97: 203-208, 2018.

27. He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.

28. Nikolov S, Dobecke C, Comoglio F, Berg T, Beck J, Boosinger-Her, Alex G, Corso J, Strelbel P, Wachter et al: HOx9 and miR-497 cooperatively induce addiction to syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell 31: 549-562, 2016.

29. Yu Y, Yoshida A, Chitnis N, Altman BJ, Tameire F, Oran A, Cerimovic V, Armeske KE, McMahon SB, Wertheim GB, et al: A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol 20: 104-115, 2018.

30. Yan W, Wu X, Zhou W, Feng MY, Cao M, Liu J, Liu X, Chen CH, Fadare O, Pizzo DP, et al: Cancer-Cell-Secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20: 597-609, 2018.

31. Cherny V, Pustylnikov V, Kozlov V and Gulyaeva L: Increased expression of miR-15a and miR-222 is associated with lymph node positive status. J Cancer 9: 135-140, 2018.

32. Leite KR, Reis ST, Viana N, Morais DR, Moura CM, Silva IA, Pontes J Jr, Katz B and Srougi M: Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J Cancer 6: 292-301, 2015.

33. Yan MZ, Cheng WC, Yu J, Shao J, Nieh S, O’Connor C, Liu CL, Tsai WW, Wu CJ, Martin L, Lin YS, et al: MiR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS. Nat Cell Biol 19: 1286-1296, 2017.

34. Yuan JH, Yang F, Chen BF, Lu Z, Hua XS, Zhou WP, Wang F and Sun SH: The histone deacetylase 4/SP1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 54: 2025-2035, 2011.
39. Ho CS, Noor SM and Nagoor NH: MiR-378 and MiR-1827 regulate tumor invasion, migration and angiogenesis in human lung adenocarcinoma by targeting RBX1 and CRKL, respectively. J Cancer 9: 331-345, 2018.

40. Jiang Z, Slater CM, Zhou Y, Devarajan K, Ruth KJ, Li Y, Cai KQ, Daly M and Chen X: LincRN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. Breast Cancer Res 19: 62, 2017.

41. Nishihiro T, Kasai M, Mori S, Watanabe T, Kuriya Y, Suda M, Kitamura M, Hirayama K, Akaishi T and Sasaki T: Characteristics of two cell lines (TE-1 and TE-2) derived from human squamous cell carcinoma of the esophagus. Gan 70: 575-584, 1979.

42. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R and Hainaut P: Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 71: 79-87, 1997.

43. Gao J, Xue KX, Li BG, Dong HY, Wei LS, Zhang ZH, Tian S and Xu ZG: Site-Dependence of invasiveness of ECA109 human oesophageal carcinoma cells in nude mice. Clin Exp Metastasis 2: 205-212, 1984.

44. Ye Z, Fang J, Dai S, Wang Y, Fu Z, Feng W, Wei Q and Huang P: MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background. Cancer Lett 370: 216-221, 2016.

45. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

46. Li RC, Ke S, Meng FK, Lu J, Zou XJ, He ZG, Wang WF and Fang MH: CiRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/FOXB13. Cell Death Dis 9: 438, 2018.

47. Higuchi T, Todaka H, Sugiyama Y, Ono M, Tamaki N, Hatano E, Takezaki Y, Hanakazi K, Miwa T, Li S, et al: Suppression of microRNA-7 (miR-7) biogenesis by nuclear factor 90-nuclear factor 45 complex (NF90-NF45) controls cell proliferation in hepatocellular carcinoma. J Biol Chem 291: 21074-21084, 2016.

48. Su C, Han Y, Zhang H, Li Y, Yi L, Wang X, Zhou S, Yu D, Song X, Xiao N, et al: CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-κB signaling. J Cell Mol Med 22: 3097-3108, 2018.

49. Xu B, Yang T, Wang Z, Zhang Y, Liu S and Shen M: CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value. Cancer Manag Res 10: 4871-4880, 2018.

50. Zhang E, Han L, Yin D, He X, Hong L, Si X, Qiu M, Xu T, De W, Xu L, et al: H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res 45: 3086-3101, 2017.

51. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et al: Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 49: 1097-1102, 2017.

52. Li CQ, Huang GW, Wu ZY, Xu YJ, Li XC, Xue YJ, Zhu Y, Zhao JM, Li M, Zhang J, et al: Integrative analyses of transcriptional sequencing identifying novel functional IncRNAs in esophageal squamous cell carcinoma. Oncogenesis 6: e297, 2017.

53. Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, Yu L, Li M, Liu C, et al: Functional role of a novel long noncoding RNA TTN-AS1 in esophageal squamous cell carcinoma progression and metastasis. Clin Cancer Res 24: 486-498, 2018.

54. Li Y, Li J, Luo M, Zhou C, Shi X, Yang W, Lu Z, Chen Z, Sun N and He J: Novel long noncoding RNA NMR promotes tumor progression via NSU2 and BPTF in esophageal squamous cell carcinoma. Cancer Lett 430: 57-66, 2018.